Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ767672B2 - Antigen binding molecules comprising a tnf family ligand trimer - Google Patents
[go: Go Back, main page]

NZ767672B2 - Antigen binding molecules comprising a tnf family ligand trimer - Google Patents

Antigen binding molecules comprising a tnf family ligand trimer Download PDF

Info

Publication number
NZ767672B2
NZ767672B2 NZ767672A NZ76767215A NZ767672B2 NZ 767672 B2 NZ767672 B2 NZ 767672B2 NZ 767672 A NZ767672 A NZ 767672A NZ 76767215 A NZ76767215 A NZ 76767215A NZ 767672 B2 NZ767672 B2 NZ 767672B2
Authority
NZ
New Zealand
Prior art keywords
seq
amino acid
domain
acid sequence
polypeptide
Prior art date
Application number
NZ767672A
Other versions
NZ767672A (en
Inventor
Maria Amann
Peter Bruenker
Christina Claus
Koller Claudia Ferrara
Richards Sandra Grau
Christian Klein
Viktor Levitski
Ekkehard Moessner
Joerg Thomas Regula
Pablo Umana
Original Assignee
F Hoffmann La Roche Ag
Filing date
Publication date
Application filed by F Hoffmann La Roche Ag filed Critical F Hoffmann La Roche Ag
Publication of NZ767672A publication Critical patent/NZ767672A/en
Publication of NZ767672B2 publication Critical patent/NZ767672B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one Fab molecule capable of specific binding to CD19 and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH1 or CL domain, a CH3 domain or a VH-CL or a VL-CH1 domain and the second polypeptide contains a CL or CH1 domain, or a VH-CL or a VL-CH1 domain, wherein the first polypeptide comprises two ectodomains of 4-1BBL and wherein the second polypeptide comprises one ectodomain of said 4-1BBL and (c) an Fc domain composed of a first and a second subunit capable of stable association.

Claims (13)

Claims
1. A TNF family ligand trimer-containing n binding molecule comprising (a) at least one Fab molecule e of specific binding to CD19, 5 (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that (i) the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first ptide by a disulfide bond between the CH1 and CL domain, and wherein the first 10 polypeptide comprises two ectodomains of 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 that are connected to each other and to the CH1 or CL domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said 4-1BBL 15 comprising the amino acid ce ed from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 ted via a peptide linker to the CL or CH1 domain of said polypeptide, or (ii) the first polypeptide contains a CH3 domain and the second polypeptide contains a 20 CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of 4-1BBL comprising the amino acid ce selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 that are connected to each other and to the C-terminus of the CH3 domain by a e linker and wherein the 25 second polypeptide comprises only one ectodomain of said 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide, or 30 (iii) the first polypeptide contains a VH-CL or a VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, tively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of 4-1BBL sing the amino acid sequence selected from the group consisting of SEQ 35 ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 that are connected to each other and to VH or VL by a peptide linker and wherein the second polypeptide comprises one ectodomain of said 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 connected via a peptide linker to VL or VH of said polypeptide, and 5 (c) an Fc domain composed of a first and a second t capable of stable association.
2. The TNF family ligand trimer-containing antigen binding molecule of claims 1 or 2, wherein the ectodomain of 4-1BBL comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96.
3. The TNF family ligand trimer-containing antigen binding molecule of claims 1 or 2, 10 wherein the ectodomain of 4-1BBL comprises the amino acid sequence of SEQ ID NO:96.
4. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 3, comprising (a) at least one Fab molecule e of specific binding to CD19 and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, 15 wherein the antigen binding molecule is characterized in that the first ptide ses the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4. 20
5. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 4, comprising (a) at least one Fab le capable of specific binding to CD19, and (b) a first polypeptide containing a CH1 or CL domain and a second polypeptide containing a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first 25 polypeptide by a disulfide bond n the CH1 and CL domain, and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1BBL comprising the amino acid ce selected from the group ting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 that are connected to 30 each other and to the CH1 or CL domain by a e linker and in that the second polypeptide comprises only one ectodomain of said 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 connected via a peptide linker to the CL or CH1 domain of said polypeptide.
6. The TNF family ligand -containing antigen binding molecule of any one of claims 1 to 5, wherein the Fc domain is an IgG, particularly an IgG1 Fc domain or an IgG4 Fc domain.
7. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 6, wherein the Fc domain is an IgG1 Fc domain comprising the amino acid substitutions at 5 positions 234 and 235 (EU numbering) and/or 329 (EU numbering).
8. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 7, wherein the antigen binding molecule comprises a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to CD19, 10 a first peptide comprising two ectodomains of 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 connected to each other by a first peptide linker fused at its inus by a second peptide linker to a second heavy or light chain, 15 and a second peptide comprising one ectodomain of said 4-1BBL comprising the amino acid sequence ed from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375 fused at its C-terminus by a third peptide linker to a second light or heavy chain, tively. 20
9. The TNF family ligand trimer-containing n binding molecule of any one of claims 1 to 8, n the antigen binding molecule comprises (a) a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to CD19, (b) a second heavy chain comprising an amino acid sequence ed from the group 25 ting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99, and a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.
10. The TNF family ligand -containing antigen binding molecule of any one of claims 1 to 9, wherein the Fab molecule capable of specific binding to CD19 comprises a VH domain 30 comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID , (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251.
11. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 10, wherein the Fab molecule capable of specific binding to CD19 comprises a variable 5 heavy chain comprising an amino acid sequence of SEQ ID NO:201 and a variable light chain comprising an amino acid ce of SEQ ID NO:202 or wherein the Fab molecule capable of specific binding to CD19 comprises a le heavy chain comprising an amino acid ce of SEQ ID NO:357 and a variable light chain comprising an amino acid ce of SEQ ID NO:358. 10
12. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 11, wherein the antigen binding molecule comprises (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or 15 a first heavy chain sing the VH domain sing the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358, (ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and 20 (iii) a second light chain sing the amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.
13. The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 11, wherein the antigen binding molecule comprises 25 (i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid 30 ce of SEQ ID NO:358, (ii) a second heavy chain comprising the amino acid sequence selected from the group ting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and (iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:
NZ767672A 2015-11-13 Antigen binding molecules comprising a tnf family ligand trimer NZ767672B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14193260 2014-11-14
EP15183736 2015-09-03
EP15188142 2015-10-02
NZ730933A NZ730933B2 (en) 2015-11-13 Antigen binding molecules comprising a tnf family ligand trimer

Publications (2)

Publication Number Publication Date
NZ767672A NZ767672A (en) 2024-02-23
NZ767672B2 true NZ767672B2 (en) 2024-05-24

Family

ID=

Similar Documents

Publication Publication Date Title
HRP20210739T1 (en) Antigen binding molecules comprising a tnf family ligand trimer
AU2020359928B2 (en) CD3-targeting antibody, bispecific antibody and use thereof
US20200024346A1 (en) Molecules with specificity for cd79 and cd22
JP2021153590A (en) Antibody molecule that binds to CD22
JP6998857B2 (en) Antibody molecule that binds to CD79
AR108452A1 (en) ANTIGEN UNION MOLECULES THAT INCLUDE A TRIMMER BINDING THE FNT FAMILY AND A FRACTION OF UNION TO TENASCINA
JP2017504578A5 (en)
JP2020508655A5 (en)
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
JP2019502694A5 (en)
IL277575B2 (en) Antibodies to chelated radionuclides
CA2896548A1 (en) Multivalent binding protein compositions
RU2012147286A (en) HUMANIZED ANTIBODIES TO FACTOR D AND THEIR APPLICATIONS
PE20210554A1 (en) ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
JP2020524510A5 (en)
RU2019124709A (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTIONS BASED ON Fc-ANTIGEN BINDING DOMAIN
JP2022512234A5 (en)
AR114436A1 (en) CANNABINOID TYPE 1 (CB1) RECEPTOR BINDING PROTEINS AND USES OF THEM
JP2017509323A5 (en)
RU2010122044A (en) IMPROVED MOLECULES RELATING TO Nogo-A AND THEIR PHARMACEUTICAL USE
US12391758B2 (en) Anti-PD-L1 cancer immunotherapy antibodies
NZ767672B2 (en) Antigen binding molecules comprising a tnf family ligand trimer
NZ730933B2 (en) Antigen binding molecules comprising a tnf family ligand trimer
NZ767674B2 (en) Antigen binding molecules comprising a tnf family ligand trimer
NZ783556A (en) Bispecific antibody against α-syn/igf1r and use thereof